ClinicalTrials.gg
CompletedNCT07062224PRODIABUpdated Nov 10, 2026

Effect of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes (PRODIAB)

An interventional study of Probiotic/Prebiotic Supplement and Placebo Gel in Diabete Type 1, sponsored by Universidad Católica San Antonio de Murcia. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Universidad Católica San Antonio de Murcia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2025, registered Jul 2025).
Updated Nov 10, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Enrollment
79th of 113
54 · median 153
Started
2025
with 17 others
No phase
55 of 150
12 open now
Registered
129th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 79th largest by enrollment of the 113 interventional ones that give a count, is one of 18 that started in 2025, is one of 55 with no phase, and was the 129th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

This randomized, double-blind clinical trial aims to evaluate the effect of a probiotic supplement on gut microbiota composition and glycemic control in adults with type 1 diabetes mellitus. A secondary comparison will be made with a healthy control group. Participants will be assigned to receive either a probiotic or a placebo for 98 days. Stool samples and metabolic parameters will be collected at baseline and after the intervention period. The study seeks to better understand how modulation of the intestinal microbiota may influence glucose regulation in people with type 1 diabetes.

Read the detailed description

This randomized, double-blind clinical trial aims to evaluate the impact of a nutritional supplement composed of inulin (prebiotic) and tyndallized probiotics (paraprobiotics) on gut microbiota composition, intestinal barrier integrity, and glycemic control in individuals with type 1 diabetes mellitus (T1D). A total of 80 participants will be recruited: 40 with T1D and 40 healthy controls. Each group will be randomly assigned to receive either the active supplement or a placebo for a period of approximately 98 days.

The study will include pre- and post-intervention assessments using stool samples (for microbiota analysis and intestinal inflammation markers like zonulin and calprotectin), continuous glucose monitor (CGM) data, blood tests (for glycemic, hepatic, renal, and lipid profiles), body composition analysis by bioimpedance (including phase angle), and validated questionnaires assessing gastrointestinal symptoms, lifestyle, dietary intake, and diabetes-related quality of life.

The main objectives are to analyze changes in gut microbiota diversity and composition, assess effects on intestinal permeability and inflammation, evaluate the safety and tolerability of the supplement, and determine its impact on metabolic markers such as fasting glucose, HbA1c, glycemic variability, and HOMA-IR.

This project seeks to explore microbiota modulation as a potential complementary therapeutic strategy for improving glycemic control and metabolic health in individuals with T1D. The supplement will be provided in 10 mL gel sticks, containing 4000 mg of inulin and 1000 mg of tyndallized probiotics, taken once daily. The intervention period has been strategically planned to avoid holidays and vacation times to ensure adherence and minimize lifestyle variability.

03

Conditions studied

  • Diabete Type 1

Keywords

  • Gut microbiota
  • Probiotic supplement
  • Zonulin
  • Calprotectin
  • Type 1 Diabetes
  • Glycemic Control
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years.
  • Ability to understand and sign the form.
  • For the patient group: diagnosis of type 1 diabetes with at least 1 year of disease progression.
  • For the control group: healthy individuals without a diagnosis of diabetes or other metabolic disorders.
  • No use of antibiotics, probiotics, or prebiotics during the 4 weeks prior to the study start.
  • Willingness to comply with the study protocol and attend scheduled visits.

Exclusion criteria

Exclusion Criteria:

  • Current use of probiotics, prebiotics, or antibiotics.
  • Chronic gastrointestinal diseases (e.g., inflammatory bowel disease, irritable bowel syndrome).
  • Pregnancy or breastfeeding.
  • Participation in another clinical trial within the past 3 months.
  • diseases, active cancer, or treatment with immunosuppressants.
  • Known allergy or intolerance to any component of the supplement or placebo.
  • Excessive alcohol or drug use.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Type 1 Diabetes - Supplement

    Participants with type 1 diabetes mellitus will receive a daily 10 mL gel supplement containing 4000 mg of inulin and 1000 mg of tyndallized probiotics for approximately 98 days. The supplement is designed to modulate gut microbiota and improve glycemic control.

    Dietary Supplement: Probiotic/Prebiotic Supplement

  • Experimental
    Type 1 Diabetes - Placebo

    Participants with type 1 diabetes mellitus will receive a daily 10 mL placebo gel without active ingredients for approximately 98 days. The placebo is organoleptically identical to the supplement to maintain blinding.

    Dietary Supplement: Placebo Gel

  • Experimental
    Healthy Controls - Supplement

    Healthy participants will receive a daily 10 mL gel supplement containing 4000 mg of inulin and 1000 mg of tyndallized probiotics for approximately 98 days. This arm allows comparison of microbiota and metabolic responses between diabetic and non-diabetic individuals.

    Dietary Supplement: Probiotic/Prebiotic Supplement

  • Experimental
    Healthy Controls - Placebo

    Healthy participants will receive a daily 10 mL placebo gel without active ingredients for approximately 98 days. The placebo is identical in appearance and flavor to the active supplement.

    Dietary Supplement: Placebo Gel

Interventions

  • Dietary supplementProbiotic/Prebiotic Supplement

    Oral dietary supplement in gel form (10 mL per day) containing 4000 mg of inulin and 1000 mg of tyndallized probiotics. Administered once daily for approximately 98 consecutive days. Produced by Martínez Nieto S.A. (MARNYS®). Intended to modulate gut microbiota and improve glycemic and inflammatory markers.

  • Dietary supplementPlacebo Gel

    Oral placebo in gel form (10 mL per day), identical in appearance, texture, and taste to the active supplement, but without probiotic or prebiotic components. Administered once daily for 98 days to maintain blinding and control effects.

06

What researchers measure

Primary outcomes

  1. Change in gut microbiota composition

    Variation in the relative abundance and diversity of gut microbiota species assessed by 16S rRNA sequencing from stool samples collected at baseline and after 98 days of intervention.

    Time frame: Baseline and 98 days post-intervention

Secondary outcomes

  1. Change in fasting glucose [Time Frame: Day 1 and Day 98]

    Assessment of changes in fasting glucose levels (mg/dL) via blood test.

    Time frame: Baseline and 98 days post-intervention

  2. Change in HbA1c [Time Frame: Day 1 and Day 98]

    Assessment of changes in glycated hemoglobin levels (HbA1c, %) via blood test.

    Time frame: Baseline and 98 days post-intervention

  3. Change in fasting insulin [Time Frame: Day 1 and Day 98]

    Assessment of changes in fasting insulin levels via blood test. μU/mL

    Time frame: Baseline and 98 days post-intervention

  4. Change in HOMA-IR index [Time Frame: Day 1 and Day 98]

    Assessment of changes in insulin resistance estimated using the HOMA-IR index.

    Time frame: Baseline and 98 days post-intervention

  5. Change in time in range (70-180 mg/dL) [Time Frame: 3 months]

    Assessment of the percentage of time that glucose levels are within the target range using continuous glucose monitoring (CGM).

    Time frame: Baseline and 98 days post-intervention

  6. Change in time above range (>180 mg/dL) [Time Frame: 3 months]

    Assessment of the percentage of time with hyperglycemia using CGM.

    Time frame: Baseline and 98 days post-intervention

  7. Change in time below range (<70 mg/dL) [Time Frame: 3 months]

    Assessment of the percentage of time with hypoglycemia using CGM.

    Time frame: Baseline and 98 days post-intervention

  8. Change in mean glucose [Time Frame: 3 months]

    Assessment of average glucose concentration (mg/dL) using CGM.

    Time frame: Baseline and 98 days post-intervention

  9. Change in glucose variability [Time Frame: 3 months]

    Assessment of glucose coefficient of variation (%) using CGM.

    Time frame: Baseline and 98 days post-intervention

  10. Change in plasma zonulin levels [Time Frame: Day 1 and Day 98]

    Zonulin levels will be measured in fasting plasma samples using ELISA at baseline and after the intervention (ng/mL).

    Time frame: Baseline and 98 days post-intervention

  11. Change in fecal calprotectin levels [Time Frame: Day 1 and Day 98]

    Calprotectin levels will be measured in stool samples using immunoassay at baseline and after the intervention (µg/g).

    Time frame: Baseline and 98 days post-intervention

07

Study locations

1 site
  • UCAM San Antonio Catholic University of Murcia
    Murcia, Murcia 30107, Spain
08

References and documents

Publications

  • Abuqwider J, Corrado A, Scida G, Lupoli R, Costabile G, Mauriello G, Bozzetto L. Gut microbiome and blood glucose control in type 1 diabetes: a systematic review. Front Endocrinol (Lausanne). 2023 Nov 15;14:1265696. doi: 10.3389/fendo.2023.1265696. eCollection 2023. PubMed 38034007 ↗
  • Stewart CJ, Nelson A, Campbell MD, Walker M, Stevenson EJ, Shaw JA, Cummings SP, West DJ. Gut microbiota of Type 1 diabetes patients with good glycaemic control and high physical fitness is similar to people without diabetes: an observational study. Diabet Med. 2017 Jan;34(1):127-134. doi: 10.1111/dme.13140. Epub 2016 May 14. PubMed 27100052 ↗

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jun 2025, 4 months.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 4 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Sep 2025 → Feb 2025 and primary completion Nov 2025 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 14, 2025
StartActual
Feb 1, 2025was Sep 2025
Primary completionActual
Jun 30, 2025was Nov 2025
CompletionActual
Dec 20, 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 10, 2026
Start date
Sep 2025→Feb 1, 2025 (actual)
Nov 10, 2026
Primary completion
Nov 2025→Jun 30, 2025 (actual)
Nov 10, 2026
Enrollment
80 (estimated)→54 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Completed
    Start date Sep 2025→Feb 1, 2025 (now actual)
    Primary completion Nov 2025→Jun 30, 2025 (now actual)
    Enrollment 80 (estimated)→54 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07062224
Responsible party
Mª Teresa Mercader Ros (Principal Investigator and Academic Secretary of the Bachelor's Degree in Human Nutrition and Dietetics at UCAM, Universidad Católica San Antonio de Murcia) — Principal investigator
First posted
Jul 14, 2025
Start date
Feb 1, 2025
Primary completion
Jun 30, 2025
Completion
Dec 20, 2025
Last update
Nov 10, 2026

Study contacts

María T Mercader Ros, PhD
principal investigator · Universidad Católica San Antonio de Murcia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion